ダナパロイド
参考資料

↑  “Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats”. Crit Care 12 (2):  R43. (2008). doi:10.1186/cc6851. PMC 2447588. PMID 18380908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447588/.
↑  Meuleman, D.G. (1992). “Orgaran (Org 10172): Its Pharmacological Profile in Experimental Models” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2):  58–65. doi:10.1159/000216296. ISSN 1424-8840. https://www.karger.com/Article/FullText/216296.
↑  Ofosu, F.A. (1992). “Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849)” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2):  66–72. doi:10.1159/000216297. ISSN 1424-8840. https://www.karger.com/Article/FullText/216297.
↑  “Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study”. Crit Care 11 (5):  R102. (2007). doi:10.1186/cc6119. PMC 2556745. PMID 17854496. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556745/.
↑  Fernandez, F. A.; Buchanan, M. R.; Hirsh, J.; Fenton, J. W.; Ofosu, F. A. (1987-06-03). “Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits”. Thrombosis and Haemostasis 57 (3):  286–293. ISSN 0340-6245. PMID 3116701. https://pubmed.ncbi.nlm.nih.gov/3116701.
1 2 3  “オルガラン静注1250単位 添付文書”. www.info.pmda.go.jp. 2021年12月22日閲覧。
↑  “[Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases”] (ドイツ語). Hamostaseologie 27 (2):  89–97. (May 2007). PMID 17479171. http://www.schattauer.de/index.php?id=1268&pii=ha07020089&no_cache=1.
↑  “Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004”. Thromb. Haemost. 95 (6):  967–81. (June 2006). doi:10.1160/TH05-07-0489. PMID 16732376. http://www.schattauer.de/index.php?id=1268&pii=th06060967&no_cache=1.
1 2  Magnani, Harry; Gallus, Alex (2006). “Heparin-induced thrombocytopenia (HIT): A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004” (英語). Thrombosis and Haemostasis 95 (06):  967–981. doi:10.1160/TH05-07-0489. ISSN 0340-6245. http://www.thieme-connect.de/DOI/DOI?10.1160/TH05-07-0489.
↑  Bidlingmaier, Christoph; Magnani, Harry N.; Girisch, Monika; Kurnik, Karin (2006). “Safety and Efficacy of Danaparoid (Orgaran®) Use in Children” (英語). Acta Haematologica 115 (3-4):  237–247. doi:10.1159/000090941. ISSN 0001-5792. https://www.karger.com/Article/FullText/90941.
↑  Magnani, H.N. (2010-04). “An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran®)” (英語). Thrombosis Research 125 (4):  297–302. doi:10.1016/j.thromres.2009.06.006. https://linkinghub.elsevier.com/retrieve/pii/S0049384809002722.
↑  Magnani, H.N. (2010-04). “A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis” (英語). Thrombosis Research 125 (4):  e171–e176. doi:10.1016/j.thromres.2009.10.008. https://linkinghub.elsevier.com/retrieve/pii/S0049384809004599.
↑  Jpj, Wester (2012). “Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? An Analysis of Case Reports”. Journal of Biometrics & Biostatistics 01 (09). doi:10.4172/scientificreports.423. https://www.omicsonline.org/scientific-reports/srep423.digital/srep423.html.
↑  Fujiyama, Shunichiro; Saitoh, Satoshi; Kawamura, Yusuke; Sezaki, Hitomi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki et al. (2017-12). “Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome” (英語). BMC Gastroenterology 17 (1):  112. doi:10.1186/s12876-017-0668-8. ISSN 1471-230X. PMC 5657117. PMID 29070023. http://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-017-0668-8.
↑  Kato, Koji; Sakaguchi, Hirotoshi; Muramatsu, Hideki; Sekiya, Yuko; Kawashima, Nozomu; Narita, Atsushi; Doisaki, Sayoko; Watanabe, Nobuhiro et al. (2018-03). “Danaparoid reduces transplant-related mortality in stem cell transplantation for children” (英語). Pediatric Transplantation 22 (2):  e13099. doi:10.1111/petr.13099. https://onlinelibrary.wiley.com/doi/10.1111/petr.13099.
↑  Machida, S; Onizuka, M; Toyosaki, M; Aoyama, Y; Kawai, H; Amaki, J; Hara, R; Ichiki, A et al. (2017-02). “Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy” (英語). Bone Marrow Transplantation 52 (2):  307–309. doi:10.1038/bmt.2016.270. ISSN 0268-3369. http://www.nature.com/articles/bmt2016270.
↑  “Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid”. Haematologica 90 Suppl:  ECR29. (November 2005). PMID 16266920. http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=16266920.
↑  Chong, B. H.; Gallus, A. S.; Cade, J. F.; Magnani, H.; Manoharan, A.; Oldmeadow, M.; Arthur, C.; Rickard, K. et al. (2001-11). “Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study”. Thrombosis and Haemostasis 86 (5):  1170–1175. ISSN 0340-6245. PMID 11816702. https://pubmed.ncbi.nlm.nih.gov/11816702.
↑  Lubenow, Norbert; Warkentin, Theodore E.; Greinacher, Andreas; Wessel, Antje; Sloane, Debi-Ann; Krahn, Erica L.; Magnani, Harry N. (2006-01). “Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s” (英語). Thrombosis Research 117 (5):  507–515. doi:10.1016/j.thromres.2005.04.011. https://linkinghub.elsevier.com/retrieve/pii/S0049384805001696.